It’s a great price to buy in if you think COVID could bounce back a bit in winter.
This looks like a classic value setup. Declining earnings shifting to growth could make Pfizer re-rate and outperform. I think I’ll buy some shares.
SCHD holds some Pfizer shares.
Seems like investors hate good news, only want the bad!
I keep telling myself people are just taking profits.
Usually when stocks fall after good earnings, there are a few possible reasons:
- The earnings beat wasn’t big enough relative to expectations.
- The market is focused on the future, and if the outlook is uncertain, people sell.
- Margins could be shrinking.
- Sector-wide challenges or cycles could be at play.
- Some investors might be moving their money to other opportunities.
These are common reasons, though not exhaustive.
It’s because I own shares, clearly.
Looks like the technicals are suggesting a dip and then a rebound. Doesn’t seem too bad.
Markets don’t always behave logically. That’s why single-stock bets are risky unless you’re okay with potential losses.
Just gives more room to DCA. 
But seriously, good news sometimes leads to drops. Hedge funds playing the game.
There’s always a reason, even if we don’t know it. Real stock movers like hedge funds often have their own expectations beyond what’s publicly available.
Executive bonuses on shareholders’ dime.
Get the jab, end up on the side effects list, then get cancer… Pfizer sucks.
Let me make this clear: the stock market is like a casino. If you’re putting your money into a single stock, research the CEO and be ready for anything. Only invest what you’re willing to lose and hang on tight.
Pfizer’s high stock price during COVID is gradually normalizing now that the pandemic is over. Earnings only play a small role here—think long-term and zoom out.
Maybe this? Link
Pfizer has high costs and doesn’t have a bright future ahead. COVID vaccine controversies could lead to political liability.